


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis ID6458

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Novo Nordisk Ltd (semaglutide)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
All About Obesity	Board of Community Health Councils in
British Liver Trust	Wales
British Obesity Society	British National Formulary
Diabetes UK	Care Quality Commission
GUTS UK	Department of Health - Northern Ireland
HEART UK	Healthcare Improvement Scotland
Hemochromotosis UK	Medicines and Healthcare products
Liver4Life	Regulatory Agency
LIVErNORTH	 National Association of Primary Care
National Obesity Forum	 National Pharmacy Association
 Network of Sikh Organisations 	NHS Confederation
Obesity Empowerment Network	 NHS Wales Joint Commissioning
Obesity Health Alliance	Committee
Obesity UK	 Scottish Medicines Consortium
 South Asian Health Foundation 	 Welsh Government
Specialised Healthcare Alliance	
	Possible comparator companies
Healthcare professional groups	 Alliance Pharmaceuticals (vitamin E)
 Association for the Study of Obesity 	Brown & Burk UK (pioglitazone)
British Association for the Study of the	Kora Healthcare (vitamin E)
Liver (BASL)	 Madrigal Pharmaceuticals (resmetirom)
British Dietetic Association	Mylan (pioglitazone)
British Geriatrics Society	Neon Healthcare (pioglitazone)
British Hepatology Pharmacy Group	Sandoz (pioglitazone)
British Nutrition Foundation	Delevent need and
British Society for Paediatric	Relevant research groups
Endocrinology and Diabetes	Genomics England MDC Clinical Trials Unit
British Society of Gastroenterology	MRC Clinical Trials Unit
Faculty of Public Health	National Institute for Health Research
Hepatitis Nurse Specialist Forum	Associated Public Health groups



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Neonatal and Paediatric Pharmacists Group Nutrition Society Obesity Management Association Royal College of Emergency Medicine Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association 	 Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) metabolic dysfunction-associated steatohepatitis ID6458 Issue date: November 2025



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.